FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 07/2024”. The Monitor is a month-to-month printed overview of enterprise capital traits within the European Healthcare & Life Sciences sector.
As of the top of July 2024 we establish the next present VC traits in Europe:
-
Whole Healthcare & Life Sciences funding reached EUR 5,279m
-
Biotech acquired 58% of the overall funding quantity (EUR 3,076m) with oncology being the main indication (50%)
-
In July, Flo Well being (United Kingdom) secures the best transaction quantity with EUR 184m, adopted by Catalym (Germany) with EUR 139m and Myricx Bio (United Kingdom) with EUR 106m
-
Normal Atlantic (United States) is probably the most energetic investor (by deal quantity), adopted by European Innovation Council Fund (Belgium) and Forbion (Netherlands)
To entry the complete report, please click on right here.
By Mathias Klozenbücher and Johannes Hyperlink